Use of Therapeutic Monitoring in Drug Monitoring and Toxicology (dmt)

1. Reinshagen M, Schutz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53:1306–14. 2. Shipkova M, Armstrong VW, Wieland E, Oellerich M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003;49:260–8. 3. Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW, Sandborn WJ. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl 2001 5;757:1–9. 4. Sauviat M, Bolon M, Boulieu R. Stability of thiopurine metabolites and thiopurine methyltransferase activity in human blood: 11. Ther Drug Monit 2005;27:213. 5. Graaf P de, Vos RM, Boer NKH de, Sinjewel A, Jharap B, Veldkamp AI, van Bodegraven AA. Chemical stability of thiopurine metabolites in erythrocytes during 6-mercaptopurine and azathioprine treatment. J Crohn Colitis 2007:1:S22 (P075).